Source: The Lancet Neurology. Unidade: FMRP
Subjects: ESCLEROSE MÚLTIPLA (TRATAMENTO), FÁRMACOS IMUNOSSUPRESSORES, ESTUDOS RANDOMIZADOS, PACIENTES (AVALIAÇÃO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KHATRI, Bhupendra et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology, v. 10, n. 6, p. 520-529, 2011Tradução . . Disponível em: https://doi.org/10.1016/S1474-4422(11)70099-0. Acesso em: 17 nov. 2024.APA
Khatri, B., Barkhof, F., Comi, G., Hartung, H. -P., Kappos, L., Montalban, X., et al. (2011). Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology, 10( 6), 520-529. doi:10.1016/S1474-4422(11)70099-0NLM
Khatri B, Barkhof F, Comi G, Hartung H-P, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, Barreira AA. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study [Internet]. The Lancet Neurology. 2011 ; 10( 6): 520-529.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/S1474-4422(11)70099-0Vancouver
Khatri B, Barkhof F, Comi G, Hartung H-P, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, Barreira AA. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study [Internet]. The Lancet Neurology. 2011 ; 10( 6): 520-529.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/S1474-4422(11)70099-0
